Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Biologic approaches, growing implants and more
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients
Two-year event-free survival comparable to matched sibling donor myeloablative transplant
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival